21 results on '"Behrens, Frank"'
Search Results
2. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
3. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study
4. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate
5. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
6. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
7. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
8. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
9. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
10. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature
11. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
12. P189 Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study
13. P173 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial
14. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
15. Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants
16. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
17. Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
18. O03 Efficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results
19. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1
20. Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
21. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.